77 results about "Membrane associated" patented technology

Methods and apparatus for implementing microfluidic analysis devices are provided. A monolithic elastomer membrane associated with an integrated pneumatic manifold allows the placement and actuation of dense arrays of a variety of fluid control structures, such as structures for isolating, routing, merging, splitting, and storing volumes of fluid. The fluid control structures can be used to implement a pathogen detection and analysis system including integrated immunoaffinity capture and analysis, such as polymerase chain reaction (PCR) and capillary electrophoresis (CE) analysis. An analyte solution can be input into the device and pumped through a series of immunoaffinity capture matrices in microfabricated chambers having antibodies targeted to the various classes of microbiological organisms such as bacteria, viruses and bacterial spores. The immunoaffinity chambers can capture, purify, and concentrate the target for further analysis steps.

The present invention provides a non-mouse, including human, pluripotential embryonic stem cell which can:(a) be maintained on feeder layers for at least 20 passages; and(b) give rise to embryoid bodies and multiple differentiated cell phenotypes in monolayer culture.The invention further provides a method of making a pluripotential embryonic stem cell comprising culturing germ cells and germ cell progenitors in a composition comprising a growth enhancing amount of basic fibroblast growth factor, leukemia inhibitory factor, membrane associated steel factor, and soluble steel factor to primordial germ cells under cell growth conditions, thereby making a pluripotential embryonic stem cell.Also provided are compositions useful to produce the pluripotent embryonic stem cells and methods of screening associated with the method of making the embryonic stem cell.

A heat sink, and cooled electronic structure and cooled electronics apparatus utilizing the heat sink are provided. The heat sink is fabricated of a thermally conductive structure which includes one or more coolant-carrying channels coupled to facilitate the flow of coolant through the coolant-carrying channel(s). The heat sink further includes a membrane associated with the coolant-carrying channel(s). The membrane includes at least one vapor-permeable region, which overlies a portion of the coolant-carrying channel(s) and facilitates removal of vapor from the coolant-carrying channel(s), and at least one orifice coupled to inject coolant onto at least one surface of the coolant-carrying channel(s) intermediate opposite ends of the channel(s).

The present invention relates to methods of immobilizing membrane-associated molecules within a sol-gel matrix. The membrane-associated molecule is embedded in the bilayer of a liposome. The molecule-liposome assembly remains functionally intact when it is immobilized within a protein and membrane-compatible sol-gel derived from polyol silane precursors or sodium silicate. The activity and stability of the entrapped membrane-associated molecule was significantly improved in macroporous silica.

A waterproof vapor-permeable shoe, including an upper part that delimits a foot insertion region; a sole, made mainly of plastic material, provided with at least one region which is diffusely perforated with through holes in the direction of a walking surface; a vapor-permeable or perforated flat element, rigidly coupled to the lower part of the sole on which the tread of the sole is formed or rigidly coupled, the flat element adapted to limit the formation of hollows in the foot insertion region at the projection of the holes of the diffusely perforated region; and a waterproof vapor-permeable membrane associated with the upper part and / or with the sole; the membrane being arranged above the flat element so as to be superimposed on the diffusely perforated region.

Novel recombinant anticoagulation proteins, methods of their use and methods of their production are described. In particular, recombinant fusions of annexin V (ANV) and Kunitz protease inhibitors (KPI) that possess potent anticoagulant activity are provided. The fusions, abbreviated ANV:KPI, utilize ANV having high affinity for phosphatidyl-L-serine with various KPI's to target serine proteases in membrane-associated coagulation complexes in the blood coagulation cascade. ANV:KPIs are potentially useful antithrombotic drugs permitting localized passivation of thrombogenic vessel walls and associated thrombi.

The present invention is a composition identified as a region of ralA binding protein 1, wherein the region neighbors a membrane-associated portion of the ralA binding protein 1, reduces transport activity and membrane association of the ralA binding protein 1 and kills cells undergoing uncontrolled cell growth in a subject that has cells undergoing uncontrolled cell growth. The region is used to generate medicines that kill malignant cells and tumorigenic cells. Medicines may be in the form of antibodies, si-RNA and small molecules that recognize the region.

The present invention relates to a method for detecting antibodies against a target antigen in a sample which comprises contacting the sample with labelled target antigen, subjecting the sample to immunoprecipitation to precipitate antibodies in the sample and detecting the presence of antibodies against the target antigen in the sample by means of the presence of labelled target antigen in the immunoprecipitate, wherein the labelled target antigen is a fusion protein comprising the target antigen and a fluorescent protein label and the presence of labelled target antigen in the immunoprecipitate is detected by means of the fluorescence of the fluorescent label. The method is particularly suitable for use where the target antigen is an autoantigen and can also be used to identify autoantigens implicated in a particular autoimmune disorder by screening serum samples from patients with a clinical phenotype indicative or suggestive of an autoimmune disorder and suitable controls. The target protein may be from the cys-loop acetyl choline receptor ion channel gene superfamily, the voltage-gated calcium, sodium or potassium ion channel gene superfamily, the glutamate receptor gene family, a receptor tyrosine kinase, or other membrane associated channels such as aquaporin gene family.

This document relates to methods and materials involved in identifying, assessing, and monitoring prostate cancer in male mammals. For example, this document provides arrays for detecting polypeptides or nucleic acids that can be used to identify prostate cancer in male mammals. In addition, methods and materials for assessing and monitoring prostate cancer in mammals are provided herein.

The invention discloses a small interfering ribonucleic acid (siRNA) of a schistosoma japonicum katsurada membrane-associated progesterone receptor component (PGMRC2) gene. The siRNA is selected from a pair or combination of any more than two pairs of nucleotide sequences shown in SEQ ID NO.1 and SEQ ID NO.2, nucleotide sequences shown in SEQ ID NO.3 and SEQ ID NO.4, nucleotide sequences shown in SEQ ID NO.5 and SEQ ID NO.6, and nucleotide sequences shown in SEQ ID NO.7 and SEQ ID NO.8. The invention also discloses application of the siRNA of the schistosoma japonicum katsurada PGMRC2 gene. By adopting the siRNA of the schistosoma japonicum katsurada PGMRC2 gene disclosed by the invention, transcription of the Sj PGMRC2 gene can be obviously restricted, and 24% of worm reduction rate can be obtained. Therefore, the siRNA of the schistosoma japonicum katsurada PGMRC2 gene can be applicable to preparation of a medicament for treating bilharziasis.

The present invention provides methods and compositions for the isolation and use of membrane proteins and other membrane associated molecules (e.g., peptides, carbohydrates, lipids, or combinations thereof). In particular, the present invention provides amphiphilic polymer compositions and methods of using the compositions to solubilize, enrich and isolate components of biological membranes, including membrane proteins, while retaining function and / or activity of the component.

A pharmaceutical composition for treating cancer or diabetes which contains the following double-stranded RNA (A) or (B):(A) a double-stranded RNA having a sequence represented by SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:8.(B) a double-stranded RNA which has a sequence of 20 to 30 nucleotides that is identical to a partial sequence of a gene encoding human plasma membrane-associated sialidase (NEU3) and contains the sequence represented by SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 8, and the double-stranded RNA inhibits the expression of a gene encoding human plasma membrane-associated sialidase (NEU3).

The invention provides means and methods for inhibiting growth of a cancer. The means in some embodiments comprise proteins and antibodies that binds an extracellular part of a membrane associated member of the epidermal growth factor (EGF) receptor family and an extracellular part of a membrane associated member of a WNT signaling pathway. Further provided are various cells and assays that are helpful in the production of the proteins, antibodies and cells.

Compositions and methods of transplanting cells by grafting strategies into solid organs (especially internal organs) are provided. These methods and compositions can be used to repair diseased organs or to establish models of disease states in experimental hosts. The method involves attachment onto the surface of a tissue or organ, a patch graft, a “bandaid-like” covering, containing epithelial cells with supporting early lineage stage mesenchymal cells. The cells are incorporated into soft gel-forming biomaterials prepared under serum-free, defined conditions comprised of nutrients, lipids, vitamins, and regulatory signals that collectively support stemness of the donor cells. The graft is covered with a biodegradable, biocompatible, bioresorbable backing used to affix the graft to the target site. The cells in the graft migrate into and throughout the tissue such that within a couple of weeks they are uniformly dispersed within the recipient (host) tissue. The mechanisms by which engraftment and integration of donor cells into the organ or tissue involve multiple membrane-associated and secreted forms of MMPs.

Methods for controlling surface topography and binding reactivity in functionalized lipid layers, including in the form of liposomes, using pH-dependent processes. During direct cell-to-cell communication, lipids on the extracellular side of plasma membranes reorganize, and membrane associated communication-related molecules co-localize. At co-localization sites, sometimes identified as rafts, the local cell surface topography and reactivity are altered. Integration of these processes on nanometer-sized lipid vesicles used as drug delivery carriers would precisely control their interactions with diseased cells minimizing toxicities. Included are pH-dependent processes on functionalized lipid bilayers demonstrating reversible sharp changes in binding reactivity within a narrow pH window. Cholesterol enables tuning of the membrane reorganization to occur at pH values not necessarily close to the reported pKa's of the constituent titratable lipids. One illustrative function of the invention is to use liposomes to deliver bioactive agents to cancer or tumor cells and compositions of specific lipids that form liposomes to deliver a biologically active agent.

The invention relates to protein of a transcription factor NAC062D. The transcription factor is an active form after a transmembrane domain is removed from a membrane-associated transcription factor NAC062, an amino acid sequence is a sequence 1 in a sequence table, and a nucleotide sequence is a sequence 2 in the sequence table. A transgenic plant culture method of importing an encoding gene of the protein of the transcription factor NAC062D into a target plant is used for importing the encoding gene of the protein of the NAC062D into the target plant, so as to obtain the transgenic plant. The transgenic plant has the features that (1) under the normal condition, the transgenic plant is basically the same with the non-transgenic plant; (2) by adding 10mu M of inducing agent beta-estrodial (beta-E), the germinating rate of the transgenic plant is lower than the germinating rate of the non-transgenic plant. The function of the transgenic plant inhibiting the seed germinating is expressed by that the germinating rate of the transgenic plant is lower than the germinating rate of the target plant. The transcription factor NAC062D for regulating and controlling the germinating of the plant seeds and the encoding gene thereof are imported into arabidopsis thaliana (ecotype columbia), and the transgenic plant is obtained, so that the transcription factor can be applied to regulate and control the seed germinating.

A method of inhibiting the morphogenesis of a host cell membrane budding virus and the resulting infection using a compound that inhibits a host cell glucosidase or glucosyltransferase. Methods of treating lipid storage diseases using compounds that inhibit glucosyltransferases.